TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Educational and economic attainment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to first sensation of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of first seizure
Endpoint domain: Adverse events/effects
Primary endpoint: cardiac re-hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Physical Activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reactive hyperemia index (RHI) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean number of ranibizumab injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Strength improvement measured in cmH(2)O
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPEF (Cough Peak Expiratory Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CEV (Cough Expiratory Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during cough
Endpoint domain: Adverse events/effects
Primary endpoint: mean change from baseline in total symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change from baseline in morning symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Expression of MUC5AC mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of MUC5AC protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to affective pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine efficacy for measles infection
Endpoint domain: Mortality/survival
Primary endpoint: Admissions to hospital for measles
Endpoint domain: Mortality/survival
Primary endpoint: Measles mortality
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in metabolic syndrome profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reintervention rate
Endpoint domain: Adverse events/effects
Primary endpoint: Surgery-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: mean villus height to crypt depth ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: density of CD3(+) intraepithelial lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HDL cholesterol improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting insulin decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in fruit and vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants eating five or more portions a day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma beta carotene concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: survival without progression
Endpoint domain: Mortality/survival
Primary endpoint: Postprandial response of plasma TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial response of large triacylglycerol-rich lipoproteins (TRLs)-TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial response of plasma hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-PRP antibody concentrations > or =1.0 microg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hSBA titers > or =1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of subjects reporting any severe (grade 3) symptom
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of symptomatic lymphocele
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of asymptomatic lymphocele
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of PMS symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Stroke Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mycelial growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mycelial extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primordia formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of early bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Successful discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bal-SARA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trust in oncologists
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cerebrovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Bone pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: TRAb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroid sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Immunological hyporesponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduction of spontaneous pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of abnormal Fx peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from hospitalization to distant metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Median progression time
Endpoint domain: Mortality/survival
Primary endpoint: Clinician-rated anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Youth-rated trait anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-rated emotion regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GLP-1 and GIP secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: goal attainment for prolapse symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent varicose veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical severity scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of heel pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: incidence of pressure ulcers (grade 2-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: relative operator exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Lesion Revascularization (TLR) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QT(c)M change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptom improvements after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social disability outcomes
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Learning outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of patients with at least 1 sign of awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fecal output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lowering of blood circulation in the femur and marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decreased distal femoral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decreased bone metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean total global score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of MRSA or VRE
Endpoint domain: Adverse events/effects
Primary endpoint: Observers' mean VAS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parental mean VAS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Invasive breast cancer events
Endpoint domain: Mortality/survival
Primary endpoint: Clinical vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Activation of cortical and subcortical brain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence rate of acute radiation esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of symptoms of acute radiation esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects on serum metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: bronchodilatory effect of deep inspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of histamine release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of stabilising measures during mesenteric traction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of amenorrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SWS (speed of walking speed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability measured by RMDQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of catch attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elbow flexion at catch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QE durations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-week lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of test and reference patches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesion properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of mild-to-moderate itching and erythema events
Endpoint domain: Adverse events/effects
Primary endpoint: heart failure hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Change in health behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean pain score after 36 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transoperative or serious postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment efficacy of lemon juice vs gentian violet in oral thrush
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Crying during mandibular block injection
Endpoint domain: Adverse events/effects
Primary endpoint: Shift in point A coordinates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total fecal anaerobes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lactobacillus spp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal ammonia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MAU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total 25-hydroxyvitamin-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in ACT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients achieving asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet O2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of celecoxib in OA of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Nontumoral perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenchymal enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean induction to abortion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall in hemoglobin after procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in daily on time without troublesome dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oral opioids required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative systemic magnesium concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects BZ-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median dose decrease from pre-treatment levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of palliation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: objective success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bladder neck mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: avoidance of physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum Uric Acid (SUA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sedation requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total time of the endoscopic session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of serum ammonia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of grade B posthepatic liver failure
Endpoint domain: Adverse events/effects
Primary endpoint: total sugars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of low birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maternal weight gain in the third trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in Hamilton Depression rating score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lead malfunction and excessive pacing thresholds
Endpoint domain: Adverse events/effects
Primary endpoint: Lead material failure
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in knowledge about the PCC's function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Confidence in speaking with and carrying out recommendations made by the PCC
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correctly answering emergency scenarios regarding PCC
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in 'A' pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marked extorsional change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual superior oblique overaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milk production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cooney and PRWE scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: View and illumination of the oropharyngeal space and vocal cords
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OHI-S scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean oral bioavailability of ALN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: surgery duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morbidity differences between SLNB and AC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total outflow facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric mean titers for all serogroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects achieving hSBA > 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: occupational status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: self-reports of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of painless procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative heart rate change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Moderate to vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral cortical oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safe sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Awakening and extubation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sevoflurane consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Absolute bioavailability of isoniazid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute bioavailability of rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of isoniazid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDG uptake in arterial walls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of Ege's test for medial meniscal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Ege's test for medial meniscal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Ege's test for medial meniscal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 1 mm of ST segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of ST segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of FS-14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Fatigue
Primary endpoint: Nailfold microcirculation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VASm improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physician VASs improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe OM incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Extent of hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes